FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108492030> ?p ?o ?g. }

• W3108492030 abstract "Abstract Background/Introduction Large randomized clinical trials have shown the efficacy of aspirin (ASA), angiotensin converting enzyme inhibitors (ACEI) and statins (S) in secondary prevention. However, adherence to medication is low in patients suffering from a cardiovascular event and decreases with each additional tablet. Therefore, a single pill (SP) approach is considered to increase drug persistence and decrease cardiovascular events in this patient population. Purpose Data that show an advantage for a SP regimen containing ASA, ACEI, and S compared to the identical loose combination (LC) regarding persistence, and clinical outcomes under conditions of daily practise in one study are missing. We conducted the START study to answer these questions. A subset, in which we anlysed data from patients in secondary prevention is presented here. Methods The START study was a retrospective, non-interventional analysis of an anonymised claims dataset covering patients suffering from cardiovascular diseases insured by the German AOK PLUS public health insurance in the years 2012–2017. Patients at age ≥18 years with an indication for the use of a combination treatment in cardiovascular disorders – including the use of ASA, ramipril, and atorvastatin - in a SP or identical LC were followed up to 1 year. After 1:1-Propensity Score Matching (PSM) persistence (defined as redemption of prescription with a lack &gt;60 days) and clinical outcomes were compared using non-parametric tests. Results Before PSM, 564,941 patients had a cardiovascular event in the medical history, 427,046 suffered from coronary artery disease. 275 received the three substances described above as SP, 6,662 as LC. After PSM, data from 211 patients were suitable for further analysis in each group. Baseline characteristics were comparable between SP and LC groups. Persistence to treatment was significant lower in the LC group (Hazard Ratio, HR, 0.25 [95% CI 0.19–0.34], p&lt;0.001). 8 clinical outcomes were analysed. Lower Incidence Rate Ratio (IRR) was found in the SP group for myocardial infarction (IRR 0.46; 95% CI 0.07–2.36), stroke (IRR 0.51; 95% CI 0.04–4.46), transitory ischemic attac (IRR 0.77; 95% CI 0.01–60.12), coronary artery disease (IRR 0.60; 95% CI 0.25–1.43), and all cause mortality (IRR 0.38; 95% CI 0.06–1.79). All cause hospitalisation was significant lower in the SP group (IRR 0.58; 95% CI 0.47–0.72; p&lt;0.001). Conclusion The number of patients receiving a SP regimen in secondary prevention was relatively low. However, persistence to medication was significantly higher in the SP group. In addition, a tendency for a lower IRR was also observed for cardiovascular events and all cause mortality in the SP group. The results of our analysis support the use of a SP regimen in secondary prevention of cardiovascular events. Funding Acknowledgement Type of funding source: None" @default.
• W3108492030 created "2020-12-07" @default.
• W3108492030 creator A5003659498 @default.
• W3108492030 creator A5011003633 @default.
• W3108492030 creator A5015836264 @default.
• W3108492030 creator A5028925264 @default.
• W3108492030 creator A5049235067 @default.
• W3108492030 creator A5049860529 @default.
• W3108492030 creator A5069931341 @default.
• W3108492030 creator A5071577321 @default.
• W3108492030 creator A5080493790 @default.
• W3108492030 creator A5085204166 @default.
• W3108492030 date "2020-11-01" @default.
• W3108492030 modified "2023-09-23" @default.
• W3108492030 title "Persistence and cardiovascular outcomes with ramipril, atorvastatin, ASA as a single pill compared to the multi pill combination. A subanalysis of the START study, a claims data analysis" @default.
• W3108492030 doi "https://doi.org/10.1093/ehjci/ehaa946.2964" @default.
• W3108492030 hasPublicationYear "2020" @default.
• W3108492030 type Work @default.
• W3108492030 sameAs 3108492030 @default.
• W3108492030 citedByCount "2" @default.
• W3108492030 countsByYear W31084920302022 @default.
• W3108492030 crossrefType "journal-article" @default.
• W3108492030 hasAuthorship W3108492030A5003659498 @default.
• W3108492030 hasAuthorship W3108492030A5011003633 @default.
• W3108492030 hasAuthorship W3108492030A5015836264 @default.
• W3108492030 hasAuthorship W3108492030A5028925264 @default.
• W3108492030 hasAuthorship W3108492030A5049235067 @default.
• W3108492030 hasAuthorship W3108492030A5049860529 @default.
• W3108492030 hasAuthorship W3108492030A5069931341 @default.
• W3108492030 hasAuthorship W3108492030A5071577321 @default.
• W3108492030 hasAuthorship W3108492030A5080493790 @default.
• W3108492030 hasAuthorship W3108492030A5085204166 @default.
• W3108492030 hasConcept C126322002 @default.
• W3108492030 hasConcept C17923572 @default.
• W3108492030 hasConcept C2426938 @default.
• W3108492030 hasConcept C2777482532 @default.
• W3108492030 hasConcept C2777628954 @default.
• W3108492030 hasConcept C2778213512 @default.
• W3108492030 hasConcept C2779888176 @default.
• W3108492030 hasConcept C2781413609 @default.
• W3108492030 hasConcept C2908647359 @default.
• W3108492030 hasConcept C535046627 @default.
• W3108492030 hasConcept C71924100 @default.
• W3108492030 hasConcept C81603835 @default.
• W3108492030 hasConcept C84393581 @default.
• W3108492030 hasConcept C98274493 @default.
• W3108492030 hasConcept C99454951 @default.
• W3108492030 hasConceptScore W3108492030C126322002 @default.
• W3108492030 hasConceptScore W3108492030C17923572 @default.
• W3108492030 hasConceptScore W3108492030C2426938 @default.
• W3108492030 hasConceptScore W3108492030C2777482532 @default.
• W3108492030 hasConceptScore W3108492030C2777628954 @default.
• W3108492030 hasConceptScore W3108492030C2778213512 @default.
• W3108492030 hasConceptScore W3108492030C2779888176 @default.
• W3108492030 hasConceptScore W3108492030C2781413609 @default.
• W3108492030 hasConceptScore W3108492030C2908647359 @default.
• W3108492030 hasConceptScore W3108492030C535046627 @default.
• W3108492030 hasConceptScore W3108492030C71924100 @default.
• W3108492030 hasConceptScore W3108492030C81603835 @default.
• W3108492030 hasConceptScore W3108492030C84393581 @default.
• W3108492030 hasConceptScore W3108492030C98274493 @default.
• W3108492030 hasConceptScore W3108492030C99454951 @default.
• W3108492030 hasIssue "Supplement_2" @default.
• W3108492030 hasLocation W31084920301 @default.
• W3108492030 hasOpenAccess W3108492030 @default.
• W3108492030 hasPrimaryLocation W31084920301 @default.
• W3108492030 hasRelatedWork W2000944526 @default.
• W3108492030 hasRelatedWork W2030720859 @default.
• W3108492030 hasRelatedWork W2098749839 @default.
• W3108492030 hasRelatedWork W2350995774 @default.
• W3108492030 hasRelatedWork W2381617719 @default.
• W3108492030 hasRelatedWork W2514731609 @default.
• W3108492030 hasRelatedWork W29179590 @default.
• W3108492030 hasRelatedWork W3108492030 @default.
• W3108492030 hasRelatedWork W4220667651 @default.
• W3108492030 hasRelatedWork W50507551 @default.
• W3108492030 hasVolume "41" @default.
• W3108492030 isParatext "false" @default.
• W3108492030 isRetracted "false" @default.
• W3108492030 magId "3108492030" @default.
• W3108492030 workType "article" @default.